2025. Targeting Cardiometabolic Risk Beyond Statins: A Systematic Review of Evolocumab in Statin-Intolerant Patients with Metabolic Syndrome. Journal of Carcinogenesis. 24, 3s (Sep. 2025), 441–448. DOI:https://doi.org/10.64149/J.Carcinog.24.3s.441-448.